Revision 1

Store at -20C

#11929

SENP1 (D16D7) Rabbit mAb

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W	H	Endogenous	76	Rabbit IgG	#Q9P0U3	29843

Product Usage Information

Application	Dilution
Western Blotting	1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

SENP1 (D16D7) Rabbit mAb recognizes endogenous levels of total SENP1 protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln175 of human SENP1 protein.

Background

SENP1 is a member of the sentrin/SUMO-specific protease (SENP) family. SENP1 localizes to the nucleoplasm and catalyzes the release of SUMO1, SUMO2, and SUMO3 monomers from sumoylated substrates (1,2). SENP1 has been reported to be responsible for intracellular SUMO homeostasis in the control of normal cellular function (2). The removal of sumoylation by SENP1 from many important target proteins, such as HDAC1, HIF-1α, Stat5, p300, Elk-1, and SirT1, leads to the regulation of the related biological pathways (3-8). SENP1-induced desumoylation of HIF-1α stabilizes the target during hypoxia (5), activating downstream VEGF expression and angiogenesis (9). SENP1 desumoylates Stat5 and contributes to Stat5 acetylation and subsequent signaling during normal lymphocyte development (6). Under stress conditions, SENP1 interacts with and inactivates SirT1 by desumoylation, protecting cells from apoptosis (8). SENP1 has been reported to target the progesterone and androgen receptors, either directly or indirectly through HDAC1, thereby upregulating their transcriptional function and potentially affecting receptor-related cancer progression (3,10-13).

Background References

1. Cheng, J. et al. (2006) *Neoplasia* 8, 667-76.
2. Bawa-Khalfe, T. and Yeh, E.T. (2010) *Genes Cancer* 1, 748-752.
3. Cheng, J. et al. (2004) *Mol Cell Biol* 24, 6021-8.
4. Cheng, J. et al. (2005) *J Biol Chem* 280, 14492-8.
5. Cheng, J. et al. (2007) *Cell* 131, 584-95.
6. Van Nguyen, T. et al. (2012) *Mol Cell* 45, 210-21.
7. Witty, J. et al. (2010) *Biochem J* 428, 247-54.
8. Yang, Y. et al. (2007) *Nat Cell Biol* 9, 1253-62.
9. Xu, Y. et al. (2010) *J Biol Chem* 285, 36682-8.
10. Kaikkonen, S. et al. (2009) *Mol Endocrinol* 23, 292-307.
11. Abdel-Hafiz, H.A. and Horwitz, K.B. (2012) *BMC Mol Biol* 13, 10.
12. Wang, Q. et al. (2012) *Oncogene* , .
13. Knutson, T.P. et al. (2012) *Breast Cancer Res* 14, R95.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting

Cross-Reactivity Key

H: Human

Trademarks and Patents

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.